GSK press releases Follow Ris-Rez reduced risk of death by 54% versus topotecan in patients with relapsed small cell lung cancer in China Longer survival achieved with fewer severe treatment-related side effects versus comparator... https://www.gsk.com/en-gb/media/press-releases/ris-rez-reduced-risk-of-death-by-54-versus-topotecan-in-patients-with-relapsed-small-cell-lung-cancer-in-china/ gsk.com
